Vander Leek Timothy K, Chan Edmond S, Connors Lori, Derfalvi Beata, Ellis Anne K, Upton Julia E M, Abrams Elissa M
Pediatric Allergy and Asthma, Department of Pediatrics, University of Alberta, 207-10430 61 Ave NW, Edmonton, AB, T6H 2J3, Canada.
Division of Allergy and Immunology, Department of Pediatrics, University of British Columbia, BC Children's Hospital, Vancouver, BC, Canada.
Allergy Asthma Clin Immunol. 2021 Mar 15;17(1):29. doi: 10.1186/s13223-021-00529-2.
Safe and effective vaccines provide the first hope for mitigating the devastating health and economic impacts resulting from coronavirus disease 2019 (COVID-19) and related public health orders. Recent case reports of reactions to COVID-19 vaccines have raised questions about their safety for use in individuals with allergies and those who are immunocompromised. In this document, we aim to address these concerns and provide guidance for allergists/immunologists.
Scoping review of the literature regarding COVID-19 vaccination, adverse or allergic reactions, and immunocompromise from PubMed over the term of December 2020 to present date. We filtered our search with the terms "human" and "English" and limited the search to the relevant subject age range with the term "adult." Reports resulting from these searches and relevant references cited in those reports were reviewed and cited on the basis of their relevance.
Assessment by an allergist is warranted in any individual with a suspected allergy to a COVID-19 vaccine or any of its components. Assessment by an allergist is NOT required for individuals with a history of unrelated allergies, including to allergies to foods, drugs, insect venom or environmental allergens. COVID-19 vaccines should be offered to immunocompromised patients if the benefit is deemed to outweigh any potential risks of vaccination.
This review provides the first Canadian guidance regarding assessment of an adolescent and adult with a suspected allergy to one of the COVID-19 vaccines currently available, or any of their known allergenic components, and for patients who are immunocompromised who require vaccination for COVID-19. As information is updated this guidance will be updated accordingly.
安全有效的疫苗为减轻2019冠状病毒病（COVID-19）及其相关公共卫生指令所带来的毁灭性健康和经济影响带来了首个希望。近期关于COVID-19疫苗反应的病例报告引发了对于其在过敏个体和免疫功能低下者中使用安全性的质疑。在本文件中，我们旨在解决这些担忧，并为过敏症专科医生/免疫学家提供指导。
对2020年12月至目前期间PubMed上关于COVID-19疫苗接种、不良反应或过敏反应以及免疫功能低下的文献进行范围综述。我们用“人类”和“英语”这两个术语筛选搜索结果，并使用“成人”一词将搜索限制在相关的主题年龄范围内。对这些搜索结果以及这些报告中引用的相关参考文献，根据其相关性进行审查和引用。
任何疑似对COVID-19疫苗或其任何成分过敏的个体都需要由过敏症专科医生进行评估。有无关过敏史的个体，包括对食物、药物、昆虫毒液或环境过敏原过敏的个体，不需要由过敏症专科医生进行评估。如果认为接种疫苗的益处大于任何潜在风险，则应向免疫功能低下的患者提供COVID-19疫苗。
本综述提供了加拿大首个关于对目前可用的一种COVID-19疫苗或其任何已知过敏原成分疑似过敏的青少年和成人，以及需要接种COVID-19疫苗的免疫功能低下患者评估的指导意见。随着信息更新，本指导意见也将相应更新。
